The application of Next-Generation Sequencing for studying the genetics of papillary thyroid carcinomas (PTC) has recently revealed new somatic mutations and gene fusions as potential new tumor-initiating events in patients without any known driver lesion. Gene and miRNA expression analyses defined clinically relevant subclasses correlated to tumor progression. In addition, it has been shown that tumor driver mutations in BRAF, and RET rearrangements - altogether termed "BRAF-like" carcinomas - have a very similar expression pattern and constitute a distinct category. Conversely, "RAS-like" carcinomas have a different genomic, epigenomic, and proteomic profile. These findings justify the need to reconsider PTC classification schemes
Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational ch...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
The concept of \u93poorly differentiated thyroid carcinoma\u94 (PDTC) was initially proposed more th...
The application of Next-Generation Sequencing for studying the genetics of papillary thyroid carcino...
Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignant neoplasia. Oncogene activat...
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the g...
Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is ...
[[abstract]]Most studies for comprehensive molecular profiling of papillary thyroid carcinoma (PTC) ...
SummaryPapillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describ...
Thyroid carcinoma is the most frequent endocrine neoplasia. Different types of thyroid carcinoma are...
Papillary thyroid carcinoma (PTC) presents distinct clinico-pathological and molecular differences i...
Background: Understanding the molecular mechanisms underlying papillary thyroid cancer (PTC) proved ...
Wisely differentiating high-risk papillary thyroid carcinoma (PTC) patients from low-risk PTC patien...
Papillary Thyroid Carcinoma (PTC) accounts for approximately 85 of patients with thyroid cancer. Des...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational ch...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
The concept of \u93poorly differentiated thyroid carcinoma\u94 (PDTC) was initially proposed more th...
The application of Next-Generation Sequencing for studying the genetics of papillary thyroid carcino...
Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignant neoplasia. Oncogene activat...
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the g...
Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is ...
[[abstract]]Most studies for comprehensive molecular profiling of papillary thyroid carcinoma (PTC) ...
SummaryPapillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describ...
Thyroid carcinoma is the most frequent endocrine neoplasia. Different types of thyroid carcinoma are...
Papillary thyroid carcinoma (PTC) presents distinct clinico-pathological and molecular differences i...
Background: Understanding the molecular mechanisms underlying papillary thyroid cancer (PTC) proved ...
Wisely differentiating high-risk papillary thyroid carcinoma (PTC) patients from low-risk PTC patien...
Papillary Thyroid Carcinoma (PTC) accounts for approximately 85 of patients with thyroid cancer. Des...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational ch...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
The concept of \u93poorly differentiated thyroid carcinoma\u94 (PDTC) was initially proposed more th...